In hepatocellular carcinoma, the METTL1/WDR4 complex promoted the translation of EGFR pathway genes via modulating m7G tRNA modification, which decreased the tumor’s susceptibility to Lenvatinib [107]. This evidence concerns the gene METTL1 and hepatocellular carcinoma.